Invivyd, Inc. (IVVD) - Earnings growth in current year

IVVD (Invivyd) - company brandmark

The annual EPS growth rate exhibits volatility, which contradicts the global rollout strategy for approved antibodies for Invivyd, Inc. (IVVD). This trend is constrained by geopolitical conflicts disrupting component logistics. However, the proprietary AI mutation forecasting system creates a competitive advantage over industry behemoths. The current value of -76.00 represents the latest metric reading, capturing the real correlation between the company's revenue and costs.

IVVD Invivyd, Inc. Earnings growth in current year (04/28/2023 - 11/12/2026)

Comprehensive metric breakdowns and analytics for invivyd.com (IVVD)

- stock price and consensus target price:
Price Performance Chart Invivyd|IVVD - Consensus Target
- market capitalization indicators:
Market Capitalization IVVD|IVVD - Total Company Value
- book capitalization data:
Net Assets per Share Invivyd, Inc.|IVVD - Book Capitalization|Market Capitalization to Book Value invivyd.com|IVVD - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio Invivyd, Inc.|IVVD - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Invivyd|IVVD - Company Aggregate Debts|Debts to Net Assets IVVD|IVVD - Company Long-Term Liabilities|Company Short-Term Debt Invivyd, Inc.|Immediate Liquidity invivyd.com
- earnings and multiples data:
IVVD - Net Profit|Net Profit Forecast Invivyd, Inc.|IVVD - Price to Earnings Ratio|Future Price to Earnings Multiple Invivyd|IVVD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio IVVD|IVVD - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Invivyd, Inc.|IVVD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months invivyd.com|IVVD - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Invivyd, Inc.
Fundamental valuation:IVVD - Invivyd Corp
Brand item of Invivyd

This indicator measures the year-over-year dynamics of net earnings per share, allowing investors to identify hidden business deceleration or corporate governance failures. An analysis of the annual earnings per share volatility for Invivyd, Inc. (IVVD) demonstrates how effectively monoclonal antibody patents are being monetized, confirming the company's ability to generate sustainable, high-margin income.

Key competitors

Gilead - Earnings per share increase in current year|Net earnings per share growth this year CDTX|Earnings growth in current year Novavax Pharma|Earnings per share growth in current year CureVac N.V. (CVAC)|Expected net earnings per share growth this year valneva.com|Earnings growth in current year VIR (Vir Biotechnology)|Expected net earnings per share growth this year SIGA Technologies Inc (SIGA)|EBS - Earnings per share growth in current year|AVIR (Atea Corp) - Earnings per share growth this year|ENTA (Enanta Pharmaceuticals) - Net earnings per share growth this year|INO (inovio.com) - Earnings per share growth in current year|HLVX (HilleVax) - Earnings growth in current year|Kalaris Therapeutics Inc. (KLRS) - Expected net earnings per share growth this year|Net earnings per share growth this year DYAI (Dyadic International)|Earnings per share growth in current year NNVC (nanoviricides.com)|Talphera, Inc. - Net earnings per share growth this year|cocrystalpharma.com (COCP) - Earnings per share growth rate in current year|Traws Therapeutics - Earnings growth in current year|DWTX (Dogwood Therapeutics, Inc.) - Earnings per share growth this year|QLGN (Qualigen) - Net earnings per share growth this year|AlloVir - Earnings per share increase in current year|VBIV (VBI Vaccines, Inc.) - Earnings growth in current year|Virios (VIRI) - Expected net earnings per share growth this year|Earnings per share growth in current year Vaxart, Inc. (VXRT)